Lorlatinib before surgery for ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests the drug lorlatinib given before surgery to shrink tumors in people with a specific genetic change (ALK rearrangement) in their lung cancer. It may help make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have lung adenocarcinoma (a type of non-small cell lung cancer) with an ALK gene change
- Your cancer is at stage IB to IIIB and can be surgically removed
- You have not had any prior treatment for your lung cancer
- Your overall health is good enough for surgery and study treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if the targeted drug lorlatinib works better than the usual combination of chemotherapy and radiation for people with a specific type of advanced lung cancer that has a change in the ALK gene. It aims to shrink tumors and stop them from growing.
This trial tests lorlatinib as a treatment before surgery for people with a type of lung cancer called non-small cell lung cancer that has an ALK gene change (ALK-positive). The goal is to understand why some tumors respond and others may not, using advanced genetic tests.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
This study looks at how people with advanced ALK-positive non-small cell lung cancer (NSCLC) respond to the targeted drug lorlatinib. It aims to understand whether local treatments (like radiation or surgery) are needed during therapy. If you have this type of lung cancer and haven't had treatment yet, this study might be an option.
Hear when a new Neoadjuvant Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.